Delaware

 

How The Inflation Reduction Act Lowers Prescription Drug Costs for Delawareans

In 2022, Congressional Democrats passed and President Biden signed into law the Inflation Reduction Act, which allows Medicare to negotiate lower drug prices, limits annual out-of-pocket prescription drug costs, caps the price of insulin at $35 per month, offers no-cost vaccines to seniors, and more. The new law also holds accountable drug companies that hike the price of their drugs faster than inflation by requiring them to pay a rebate to Medicare.

 

The impact of lower prescription drug costs thanks to the Inflation Reduction Act will be felt by thousands of Delawareans.

State Fact Sheet

 

Learn more about how the Inflation Reduction Act will help Delawareans save on health care costs

Medicare Negotiations

Helping over 35,000 Delawareans who pay hundreds or thousands out of pocket for the first 10 drugs Medicare is currently negotiating lower prices for.

full fact sheet

$2,000 Cost Cap

63,350 Delawareans seniors will save an average of $448.51 thanks to the Inflation Reduction Act’s $2,000 annual out-of-pocket cost cap, effective in 2025.

full fact sheet

$35 Insulin Cost Cap

Helping 6,066 Delawareans who use insulin.

full fact sheet

Negotiating lower prices on certain popular high-cost drugs will help:

  • 13,000 Delawareans who pay an average of $456 out-of-pocket per year for Eliquis, sold by Bristol Myers Squibb, to treat blood clots. 
  • 5,000 Delawareans who pay an average of $333 out-of-pocket per year for Jardiance, sold by Boehringer Ingelheim, to treat diabetes.
  • 6,000 Delawareans who pay an average of $488 out-of-pocket per year for Xarelto, sold by Johnson & Johnson, to treat blood clots.
  • 3,000 Delawareans who pay an average of $319 out-of-pocket per year for Januvia, sold by Merck, to treat diabetes. 
  • 3,000 Delawareans who pay an average of $307 out-of-pocket per year for Farxiga, sold by AstraZeneca to treat diabetes.
  • 2,000 Delawareans who pay an average of $384 out-of-pocket per year for Entresto, sold by Novartis, to treat heart failure. 
  • Delawareans who pay an average of $725 out-of-pocket per year for Enbrel, sold by Amgen, to treat arthritis and psoriasis.
  • Delawareans who pay an average of $4,337 out-of-pocket per year for Imbruvica, sold by AbbVie, to treat blood cancers.
  • Delawareans who pay an average of $1,854 out-of-pocket per year for Stelara, sold by Johnson & Johnson, to treat psoriasis and Crohn’s disease.
  • 3,000 Delawareans who pay an average of $145 out-of-pocket per year for Fiasp/NovoLog, sold by Novo Nordisk, to treat diabetes.

Learn about another state: